Equity Profile

TXG

10x Genomics, Inc.

Health CareLife Sciences Tools & Services$5.3B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

10x Genomics, Inc. (TXG) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market demand and overall business expansion.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TXG Q2-2026 Earnings Preview

Context

Company Snapshot

10x Genomics, Inc. (TXG) operates in the health care sector, focusing on life sciences tools and services. The company develops innovative technologies that enable researchers to analyze biological systems at a single-cell level, which is crucial for advancements in genomics and personalized medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+43.83%

Avg Stock Reaction

+0.03%

Last Quarter Recap

In Q1-2026, 10x Genomics reported an EPS of -$0.10, which was better than the expected -$0.29, resulting in a positive surprise of nearly 66%. However, the stock fell slightly by 1.41% the following day, indicating mixed market reactions.

Management Promises & Guidance

Management has committed to continuing innovation in their product offerings.
They aim to expand their customer base in the life sciences sector.
Focus on improving operational efficiencies to enhance profitability.

Expectations

Wall Street Expectations

Overall expectations for 10x Genomics are cautious, given the lack of analyst estimates and management guidance. Investors are looking for signs of sustained growth and profitability.

Bull Case

If the company continues to beat EPS estimates as it has historically, it could signal strong operational performance and market demand for its products.

Bear Case

Conversely, any signs of declining revenue or inability to meet previous performance levels could lead to negative sentiment and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given the company's history of beating EPS estimates, this will be a critical indicator of ongoing operational success.

What are the revenue figures, and how do they compare to previous quarters?

Revenue performance will provide insight into market demand and the effectiveness of the company's growth strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new product launches, which could significantly impact overall performance this quarter.

Supporting Evidence

The company's history of beating EPS estimates suggests they may outperform expectations again.

Options pricing indicates a significant move, which could reflect investor anticipation of positive news.

Recent innovations in their product line may not be fully accounted for in current revenue projections.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether the company can maintain its growth trajectory and profitability amidst market pressures.

Bull Confirmed If

An EPS of $0.00 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS of -$0.20 or worse would confirm the bear case and suggest ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±30.9%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened volatility expectations around the earnings report.

Options are pricing ±30.9% while TXG has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

69.6%

Calls (444K)P/C Ratio: 0.03Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If 10x Genomics beats expectations, history suggests the stock could rise by around 3.1%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses expectations, the average historical reaction suggests a potential decline of about 1.5%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into customer acquisition and retention strategies.
3Management's outlook on market conditions and competitive landscape.
4Discussion on operational efficiencies and cost management initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

10x Genomics, Inc. (TXG) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market demand and overall business expansion.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TXG Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+43.83%

Avg Stock Reaction

+0.03%

Last Quarter Recap

Management Promises & Guidance

Management has committed to continuing innovation in their product offerings.
They aim to expand their customer base in the life sciences sector.
Focus on improving operational efficiencies to enhance profitability.

Expectations

Wall Street Expectations

Overall expectations for 10x Genomics are cautious, given the lack of analyst estimates and management guidance. Investors are looking for signs of sustained growth and profitability.

Bull Case

If the company continues to beat EPS estimates as it has historically, it could signal strong operational performance and market demand for its products.

Bear Case

Conversely, any signs of declining revenue or inability to meet previous performance levels could lead to negative sentiment and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given the company's history of beating EPS estimates, this will be a critical indicator of ongoing operational success.

What are the revenue figures, and how do they compare to previous quarters?

Revenue performance will provide insight into market demand and the effectiveness of the company's growth strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new product launches, which could significantly impact overall performance this quarter.

Supporting Evidence

The company's history of beating EPS estimates suggests they may outperform expectations again.

Options pricing indicates a significant move, which could reflect investor anticipation of positive news.

Recent innovations in their product line may not be fully accounted for in current revenue projections.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether the company can maintain its growth trajectory and profitability amidst market pressures.

Bull Confirmed If

An EPS of $0.00 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS of -$0.20 or worse would confirm the bear case and suggest ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±30.9%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened volatility expectations around the earnings report.

Options are pricing ±30.9% while TXG has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

69.6%

Calls (444K)P/C Ratio: 0.03Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If 10x Genomics beats expectations, history suggests the stock could rise by around 3.1%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses expectations, the average historical reaction suggests a potential decline of about 1.5%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into customer acquisition and retention strategies.
3Management's outlook on market conditions and competitive landscape.
4Discussion on operational efficiencies and cost management initiatives.